Haemonetics stock kpis
Want to see HAE full AI Analyst Report?
Net Revenue by Segment
Haemonetics reported net revenue by segment of $357.76M in Q2 FY2027, up 5.4% from Q1 FY2027 and up 9.3% year over year. This is the highest value since 2021.
Tracks sales across product and service lines, showing which offerings—such as devices, consumables, and service contracts—are driving growth. For Haemonetics, a rising share of consumables or recurring service revenue points to steadier, more predictable cash flow tied to an installed base, while reliance on one-time equipment sales can make top-line performance more cyclical.
Recent quarter shows a dramatic Apheresis jump that aligns with management’s Apheresis disclosure—part real growth from Persona PLUS rollout and part reporting/reclassification, so treat it as both product momentum and a structural change. MedSurg exhibits sustained, multi‑quarter strength and supports upgraded guidance, while Plasma is steady but management remains cautious on volumes. Blood Center and Other have slumped—timing and working‑capital boosts inflated cash; watch margin pressure and OEM/IVT softness for downside risk.
HAE Net Revenue by Segment
| Period | Other | Plasma | Blood Center | Apheresis | Medsurg | Total |
|---|---|---|---|---|---|---|
| Q2 FY2027Sep 30, 2026 | $0.00 | $0.00 | $0.00 | $204.81M | $152.95M | $357.76M |
| Q1 FY2027Jun 30, 2026 | $0.00 | $0.00 | $0.00 | $191.32M | $148.06M | $339.38M |
| Q4 FY2026Mar 31, 2026 | $0.00 | $130.30M | $56.40M | $0.00 | $159.60M | $346.30M |
| Q3 FY2026Dec 31, 2025 | $0.00 | $138.91M | $56.56M | $0.00 | $143.50M | $338.97M |
| Q2 FY2026Sep 30, 2025 | $0.00 | $125.36M | $56.45M | $0.00 | $145.50M | $327.31M |
| Q1 FY2026Jun 30, 2025 | $0.00 | $129.90M | $51.84M | $0.00 | $139.66M | $321.39M |
| Q4 FY2025Mar 31, 2025 | $0.00 | $126.74M | $56.01M | $0.00 | $147.86M | $330.60M |
| Q3 FY2025Dec 31, 2024 | $0.00 | $134.22M | $70.34M | $0.00 | $143.97M | $348.54M |
| Q2 FY2025Sep 30, 2024 | $0.00 | $138.56M | $68.53M | $0.00 | $138.42M | $345.51M |
| Q1 FY2025Jun 30, 2024 | $0.00 | $135.91M | $66.25M | $0.00 | $134.02M | $336.17M |
| Q4 FY2024Mar 31, 2024 | $4.42M | $138.45M | $71.13M | $0.00 | $129.29M | $343.29M |
| Q3 FY2024Dec 31, 2023 | $4.12M | $146.72M | $71.61M | $0.00 | $113.79M | $336.25M |
| Q2 FY2024Sep 30, 2023 | $4.17M | $141.75M | $68.91M | $0.00 | $103.36M | $318.18M |
| Q1 FY2024Jun 30, 2023 | $6.01M | $138.48M | $67.31M | $0.00 | $99.54M | $311.33M |
| Q4 FY2023Mar 31, 2023 | -$453.00K | $131.99M | $70.31M | $0.00 | $102.57M | $304.42M |
| Q3 FY2023Dec 31, 2022 | -$1.99M | $136.57M | $76.83M | $0.00 | $93.89M | $305.30M |
| Q2 FY2023Sep 30, 2022 | $383.00K | $128.89M | $75.65M | $0.00 | $92.56M | $297.49M |
| Q1 FY2023Jun 30, 2022 | $2.66M | $103.04M | $66.57M | $0.00 | $89.18M | $261.46M |
| Q4 FY2022Mar 31, 2022 | $4.57M | $101.45M | $73.02M | $0.00 | $85.97M | $265.00M |
| Q3 FY2022Dec 31, 2021 | $6.45M | $96.69M | $74.53M | $0.00 | $82.10M | $259.77M |
| Q2 FY2022Sep 30, 2021 | $6.73M | $82.00M | $75.26M | $0.00 | $75.90M | $239.90M |
| Q1 FY2022Jun 30, 2021 | $7.38M | $71.80M | $71.74M | $0.00 | $77.61M | $228.53M |

